

Noile-Immune to exhibit at Japan Healthcare Venture Summit 2026 co-held with BioJapan 2026

Noile-Immune Biotech Inc. (hereinafter referred to as “Noile-Immune”) will exhibit at Japan Healthcare Venture Summit 2026, which will be co-held with BioJapan 2026 at Pacifico Yokohama from October 7 to October 9, 2026. At the exhibition booth, Noile-Immune will introduce our unique PRIME technology, an innovative approach to enhance the therapeutic effects of immune cell therapy, and will make a presentation at the "JHVS SHOWCASE" held on the stage at JHVS venue on October 8. In addition, Noile-Immune will participate in the 1 on 1 meetings using the partnering system.

Further, Noile-Immune was adopted for “FY2025 Yamaguchi advancements in practical application and industrialization of regenerative medicine (3 years at the most)”, and is steadily advancing the project in 2026, the second year. Our PRIME technology will also be featured at the Yamaguchi Prefectural Industrial Technology Center’s exhibition booth (Booth No. R-43) at Regenerative Medicine Japan 2026, which will be held at the same venue.

Exhibition Overview

- Event Name: Japan Healthcare Venture Summit 2026 (JHVS 2026)
- Official Website: <https://mediso.mhlw.go.jp/jhvs2026/>
- Dates: October 7 (Wed) – October 9 (Fri), 2026
- Venue: Pacifico Yokohama (1-1-1 Minatomirai, Nishi-ku, Yokohama City, Kanagawa Prefecture)
- Exhibition Booth: Booth No. V-13
- Presentation: Thursday, October 8, 11:00 a.m.–12:00 p.m. (JHVS Venue Stage)

<For Your Reference>

BioJapan 2026 / Regenerative Medicine Japan 2026: <https://jcd-expo.jp/>

Under the corporate philosophy, “Create the Future to Overcome Cancer,” we are engaged in research and development of next-generation cancer immunotherapies for solid tumors using our unique PRIME technology. We have established a hybrid business model with two elements: “in-house drug discovery,” i.e., drug discovery led by our company, and a “co-pipeline” in which drug development is pursued by licensing PRIME technology to other companies. In addition, we are conducting research on new pipelines and next-generation technologies, and we aim to further enhance our corporate value by delivering innovative treatments to patients around the world.

Contact for inquiries or additional information

2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan

Noile-Immune Biotech Inc.

pr@noile-immune.com